Lilly 3Q Revenues: $5.4 billion (-11%) 3Q Earnings: $1.3 billion (+7%) YTD Revenues: $16.6 billion (-9%) YTD Earnings: $3.3 billion (-7%) Comments: Revenue drop in the quarter was driven by Zyprexa patent expirations (sales down 68% to $374.5 million) and a 3% unfavorable effect of foreign exchange. Earnings would have been flat without Amylin’s $1.3 billion early payment of its exenatide revenue-sharing obligation. Total revenue in the U.S. was down 9% to $3.0 billion, primarily due to Zyp...